APOBEC3A/B/G (5210-87-13) Rabbit Monoclonal Antibody #81001
- WB
Product Specifications
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 35 |
| Source/Isotype | Rabbit |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Simple Western™ | 1:10 - 1:50 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
APOBEC3A expression is upregulated in several human cancers, and is a major source of mutation in breast cancer (6). APOBEC3A contributes to chromosomal instability and disease progression in pancreatic cancer (7), and upregulates PD-L1 expression in cancer cells (8).
APOBEC3G suppresses the replication of HIV-1 in T cells (9,10). The HIV-1 virion infectivity factor (Vif) inhibits APOBEC3G activity and targets it for proteasomal ubiquitination degradation (11).
- Olson, M.E. et al. (2018) Cell Chem Biol 25, 36-49.
- Siriwardena, S.U. et al. (2016) Chem Rev 116, 12688-12710.
- Cescon, D.W. and Haibe-Kains, B. (2016) Genome Biol 17, 202.
- Zou, J. et al. (2017) Cell Biosci 7, 29.
- Schmitt, C. et al. (2018) Oncol Rep 40, 2742-2749.
- Cortez, L.M. et al. (2019) PLoS Genet 15, e1008545.
- Wörmann, S.M. et al. (2021) Nat Cancer 2, 1338-1356.
- Zhao, K. et al. (2021) Mol Cancer Res 19, 1571-1582.
- Sheehy, A.M. et al. (2002) Nature 418, 646-50.
- Harris, R.S. et al. (2003) Cell 113, 803-9.
- Sheehy, A.M. et al. (2003) Nat Med 9, 1404-7.
Alternate Names
A3B; ABC3B; APOBEC1L; APOBEC3B; apolipoprotein B mRNA editing enzyme catalytic subunit 3B; apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B; ARCD3; ARP4; bK150C2.2; cytidine deaminase; DJ742C19.2; DNA dC->dU-editing enzyme APOBEC-3B; FLJ21201; phorbolin 2; phorbolin 3; Phorbolin-1-related protein; Phorbolin-2/3; PHRBNL; Probable DNA dC->dU-editing enzyme APOBEC-3B
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.